Clostridioides difficile

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis […]